TDP-43 Storing Cell Model for Neurodegenerative Disease Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack a reliable cell model to study the mechanism of TDP-43 accumulation and its cytotoxicity in neurodegenerative diseases like ALS and FTLD, hindering the development of therapeutic drugs and understanding of disease onset.
Innovation Solution
A transformed cell model is created by introducing a mutant TDP-43 gene into host cells, allowing for the formation of intracellular inclusions similar to those found in patient brains, and using proteasome inhibition to replicate TDP-43 accumulation, enabling the screening of therapeutic drugs and assessment of side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a cell model is developed to study TDP-43 accumulation mechanism, then understanding of disease onset and drug development are facilitated, but currently no reliable cell model exists to replicate TDP-43 inclusions
Solution Approach 1:
The patent creates a cell model that copies the pathological features of TDP-43 inclusions found in patient brains by introducing mutant TDP-43 genes into cultured cells. This allows replication of the disease state in a controlled experimental system, enabling reliable study of inclusion formation mechanisms and screening of therapeutic compounds.
2Manufacturing precision
If mutant TDP-43 gene is introduced into host cells to form inclusions, then the cell model can replicate disease pathology, but the complexity of the system increases
Solution Approach 1:
The patent segments the complex disease process into manageable components by focusing specifically on introducing mutant TDP-43 genes into cultured cells to reproduce the key pathological feature (inclusions). This segmented approach allows systematic study of inclusion formation without needing to replicate all aspects of the disease simultaneously.
3Quantity of substance
If proteasome inhibition is used to replicate TDP-43 accumulation, then inclusion formation is enhanced, but the mechanism of accumulation becomes more complex to study
Solution Approach 1:
The patent uses proteasome inhibition as an intermediary手段 to enhance TDP-43 accumulation and inclusion formation in the cell model. By blocking the proteasome pathway, the system accumulates mutant TDP-43 more efficiently, making the inclusions more prominent and easier to study despite the added complexity of the accumulation mechanism.
Data Source
AI summary
Disclosed is a transformed cell (a cell model) which can form a cytoplasmic inclusion body derived from TAR DNA-binding protein of 43 kDa (TDP-43) that is found in the brain of a patient suffering from a neurodegenerative disease such as FTLD and ALS. The transformed cell is characterized by having, introduced therein, a promoter capable of functioning in a host cell and a mutant TDP-43 gene.